European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Thyroid, Cardiology) - Forecasts to 2020
The European nuclear medicine/radiopharmaceuticals market is segmented on the basis of type, application, and country. The European nuclear medicine/radiopharmaceuticals market is valued at USD 1.095 billion in 2015 and is poised to grow at a CAGR of 8.2% during the forecasted period.
Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, cyclotron based production are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.
Some of the major players in the European nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the European market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
Factors such as increasing preference for SPECT and PET scans, advances in radiotracers, advent of alpha radio immunotherapy-based targeted cancer treatment, increasing incidence & mortality rate of cancer and cardiac ailments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, cyclotron based production are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, competition from conventional diagnostic procedures are hindering the growth of this market.
Some of the major players in the European nuclear medicine/radiopharmaceuticals market include Cardinal Health Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the European market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the European nuclear medicine/radiopharmaceuticals market. The report analyzes the European nuclear medicine/radiopharmaceuticals market by type, application, and country
- Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the European nuclear medicine/radiopharmaceuticals market
- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various European nuclear medicine/radiopharmaceuticals technologies across Europe
- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the European nuclear medicine/radiopharmaceuticals market
- Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the European nuclear medicine/radiopharmaceuticals market
1 INTRODUCTION
1.1 OBJECTIVES OF STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY STEPS
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.2 PRIMARY RESEARCH
2.2.3 KEY INDUSTRY INSIGHTS
2.3 KEY DATA FROM PRIMARY SOURCES
2.4 KEY INSIGHTS FROM PRIMARY SOURCES
2.5 MARKET SIZE ESTIMATION METHODOLOGY
2.6 RESEARCH DESIGN
2.7 MARKET DATA VALIDATION AND TRIANGULATION
2.8 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
4 PREMIUM INSIGHTS
4.1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY COUNTRY AND APPLICATION
4.3 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY
4.4 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing preference for SPECT and PET scans
5.2.1.2 Advances in radiotracers
5.2.1.3 Alpha radioimmunotherapy-based targeted cancer treatment
5.2.1.4 Growing incidence rate of cancer and cardiac ailments
5.2.2 RESTRAINTS
5.2.2.1 Shorter half-life of radiopharmaceuticals
5.2.2.2 Competition from conventional diagnostic procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Potential radioisotopes in the pipeline
5.2.3.2 Cyclotron-based production
5.2.4 CHALLENGE
5.2.4.1 Shutdown of nuclear reactors
5.2.5 BURNING ISSUE
5.2.5.1 Low healthcare spending in Europe
5.3 REGULATORY SCENARIO
5.3.1 INTRODUCTION
5.3.2 GERMANY
5.3.2.1 German Medicinal Products Act (AMG)
5.3.2.2 Amendments to the German Medicinal Products Act (AMG)
5.3.3 FRANCE
5.3.3.1 Agence Nationale de S?curit? du M?dicament et des Produits de Sant? (ANSM)
5.3.4 U.K.
5.3.4.1 The Medicines and Healthcare Products Regulatory Agency (MHRA)
5.3.5 SPAIN
5.3.6 ITALY
5.3.6.1 The Italian Pharmaceutical Agency (AIFA)
5.3.7 RUSSIA
5.3.7.1 The Federal Law
5.3.8 SWITZERLAND
5.3.8.1 Federal Department Of Home Affairs (FDHA)- The Ultimate Decision Maker
5.3.8.2 The Swiss Agency For Therapeutic Products (SATP)
6 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, PIPELINE ASSESSMENT
6.1 INTRODUCTION
6.2 DIAGNOSTIC RADIOISOTOPES
6.2.1 F-18
6.3 THERAPEUTIC RADIOISOTOPES
6.3.1 RA-223
6.3.2 LU-177
7 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
7.2.1 SPECT RADIOPHARMACEUTICALS
7.2.1.1 Technetium-99m
7.2.1.2 Thallium-201
7.2.1.3 Gallium-67
7.2.1.4 Iodine-123
7.2.1.5 Others
7.2.2 PET RADIOPHARMACEUTICALS
7.2.2.1 Fluorine-18
7.2.2.2 Rubidium-82
7.2.2.3 Others
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
7.3.1 BETA EMITTERS
7.3.1.1 Iodine-131
7.3.1.2 Yttrium-90
7.3.1.3 Samarium-153
7.3.1.4 Rhenium-186
7.3.1.5 Lutetium-177
7.3.1.6 Others
7.3.2 ALPHA EMITTERS
7.3.2.1 Radium-223
7.3.3 BRACHYTHERAPY
7.3.3.1 Iodine-125
7.3.3.2 Iridium-192
7.3.3.3 Palladium-103
7.3.3.4 Cesium-131
7.3.3.5 Others
8 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 SPECT APPLICATIONS
8.2.1.1 Cardiology
8.2.1.2 Lymphoma
8.2.1.3 Neurology
8.2.1.4 Thyroid
8.2.1.5 Other SPECT Applications
8.2.2 PET APPLICATIONS
8.2.2.1 Oncology
8.2.2.2 Cardiology
8.2.2.3 Neurology
8.2.2.4 Other PET Applications
8.3 THERAPEUTIC APPLICATIONS
8.3.1 THYROID
8.3.2 BONE METASTASIS
8.3.3 LYMPHOMA
8.3.4 ENDOCRINE TUMORS
8.3.5 OTHER THERAPEUTIC APPLICATIONS
9 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS, PROCEDURAL VOLUME
9.1 INTRODUCTION
9.2 EUROPEAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME
9.2.1 SPECT RADIOPHARMACEUTICALS
9.2.2 PET RADIOPHARMACEUTICALS
9.3 EUROPEAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME
9.3.1 BETA EMITTERS
9.3.2 ALPHA EMITTERS
9.3.3 BRACHYTHERAPY
10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY/REGION
10.1 INTRODUCTION
10.2 GERMANY
10.3 FRANCE
10.4 ITALY
10.5 U.K.
10.6 SPAIN
10.7 RUSSIA
10.8 REST OF EUROPE (ROE)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE SITUATION AND TRENDS
11.2.1 INTRODUCTION
11.2.2 AGREEMENTS & CONTRACTS
11.2.3 ACQUISITIONS
11.2.4 MARKET DEVELOPMENTS
11.2.5 EXPANSIONS
11.2.6 OTHER STRATEGIES
12 COMPANY PROFILES
(Overview, Financials, Products & Services, Strategy, and Developments)*
12.1 CARDINAL HEALTH, INC.
12.2 MALLINCKRODT PLC
12.3 GE HEALTHCARE
12.4 LANTHEUS MEDICAL IMAGING, INC.
12.5 BAYER HEALTHCARE
12.6 BRACCO IMAGING S.P.A
12.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS
12.8 NORDION, INC.
12.9 ADVANCED ACCELERATOR APPLICATIONS S.A.
12.10 IBA MOLECULAR IMAGING
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 AVAILABLE CUSTOMIZATIONS
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 RELATED REPORTS
1.1 OBJECTIVES OF STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY STEPS
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.2 PRIMARY RESEARCH
2.2.3 KEY INDUSTRY INSIGHTS
2.3 KEY DATA FROM PRIMARY SOURCES
2.4 KEY INSIGHTS FROM PRIMARY SOURCES
2.5 MARKET SIZE ESTIMATION METHODOLOGY
2.6 RESEARCH DESIGN
2.7 MARKET DATA VALIDATION AND TRIANGULATION
2.8 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
4 PREMIUM INSIGHTS
4.1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY COUNTRY AND APPLICATION
4.3 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY
4.4 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing preference for SPECT and PET scans
5.2.1.2 Advances in radiotracers
5.2.1.3 Alpha radioimmunotherapy-based targeted cancer treatment
5.2.1.4 Growing incidence rate of cancer and cardiac ailments
5.2.2 RESTRAINTS
5.2.2.1 Shorter half-life of radiopharmaceuticals
5.2.2.2 Competition from conventional diagnostic procedures
5.2.3 OPPORTUNITIES
5.2.3.1 Potential radioisotopes in the pipeline
5.2.3.2 Cyclotron-based production
5.2.4 CHALLENGE
5.2.4.1 Shutdown of nuclear reactors
5.2.5 BURNING ISSUE
5.2.5.1 Low healthcare spending in Europe
5.3 REGULATORY SCENARIO
5.3.1 INTRODUCTION
5.3.2 GERMANY
5.3.2.1 German Medicinal Products Act (AMG)
5.3.2.2 Amendments to the German Medicinal Products Act (AMG)
5.3.3 FRANCE
5.3.3.1 Agence Nationale de S?curit? du M?dicament et des Produits de Sant? (ANSM)
5.3.4 U.K.
5.3.4.1 The Medicines and Healthcare Products Regulatory Agency (MHRA)
5.3.5 SPAIN
5.3.6 ITALY
5.3.6.1 The Italian Pharmaceutical Agency (AIFA)
5.3.7 RUSSIA
5.3.7.1 The Federal Law
5.3.8 SWITZERLAND
5.3.8.1 Federal Department Of Home Affairs (FDHA)- The Ultimate Decision Maker
5.3.8.2 The Swiss Agency For Therapeutic Products (SATP)
6 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, PIPELINE ASSESSMENT
6.1 INTRODUCTION
6.2 DIAGNOSTIC RADIOISOTOPES
6.2.1 F-18
6.3 THERAPEUTIC RADIOISOTOPES
6.3.1 RA-223
6.3.2 LU-177
7 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
7.2.1 SPECT RADIOPHARMACEUTICALS
7.2.1.1 Technetium-99m
7.2.1.2 Thallium-201
7.2.1.3 Gallium-67
7.2.1.4 Iodine-123
7.2.1.5 Others
7.2.2 PET RADIOPHARMACEUTICALS
7.2.2.1 Fluorine-18
7.2.2.2 Rubidium-82
7.2.2.3 Others
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS
7.3.1 BETA EMITTERS
7.3.1.1 Iodine-131
7.3.1.2 Yttrium-90
7.3.1.3 Samarium-153
7.3.1.4 Rhenium-186
7.3.1.5 Lutetium-177
7.3.1.6 Others
7.3.2 ALPHA EMITTERS
7.3.2.1 Radium-223
7.3.3 BRACHYTHERAPY
7.3.3.1 Iodine-125
7.3.3.2 Iridium-192
7.3.3.3 Palladium-103
7.3.3.4 Cesium-131
7.3.3.5 Others
8 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DIAGNOSTIC APPLICATIONS
8.2.1 SPECT APPLICATIONS
8.2.1.1 Cardiology
8.2.1.2 Lymphoma
8.2.1.3 Neurology
8.2.1.4 Thyroid
8.2.1.5 Other SPECT Applications
8.2.2 PET APPLICATIONS
8.2.2.1 Oncology
8.2.2.2 Cardiology
8.2.2.3 Neurology
8.2.2.4 Other PET Applications
8.3 THERAPEUTIC APPLICATIONS
8.3.1 THYROID
8.3.2 BONE METASTASIS
8.3.3 LYMPHOMA
8.3.4 ENDOCRINE TUMORS
8.3.5 OTHER THERAPEUTIC APPLICATIONS
9 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS, PROCEDURAL VOLUME
9.1 INTRODUCTION
9.2 EUROPEAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME
9.2.1 SPECT RADIOPHARMACEUTICALS
9.2.2 PET RADIOPHARMACEUTICALS
9.3 EUROPEAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME
9.3.1 BETA EMITTERS
9.3.2 ALPHA EMITTERS
9.3.3 BRACHYTHERAPY
10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY COUNTRY/REGION
10.1 INTRODUCTION
10.2 GERMANY
10.3 FRANCE
10.4 ITALY
10.5 U.K.
10.6 SPAIN
10.7 RUSSIA
10.8 REST OF EUROPE (ROE)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE SITUATION AND TRENDS
11.2.1 INTRODUCTION
11.2.2 AGREEMENTS & CONTRACTS
11.2.3 ACQUISITIONS
11.2.4 MARKET DEVELOPMENTS
11.2.5 EXPANSIONS
11.2.6 OTHER STRATEGIES
12 COMPANY PROFILES
(Overview, Financials, Products & Services, Strategy, and Developments)*
12.1 CARDINAL HEALTH, INC.
12.2 MALLINCKRODT PLC
12.3 GE HEALTHCARE
12.4 LANTHEUS MEDICAL IMAGING, INC.
12.5 BAYER HEALTHCARE
12.6 BRACCO IMAGING S.P.A
12.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS
12.8 NORDION, INC.
12.9 ADVANCED ACCELERATOR APPLICATIONS S.A.
12.10 IBA MOLECULAR IMAGING
*Details on overview, financials, product & services, strategy, and developments might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 AVAILABLE CUSTOMIZATIONS
13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.4 RELATED REPORTS
LIST OF TABLES
Table 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 5 LOW HEALTHCARE SPENDING IN EUROPE IS A MAJOR BURNING ISSUE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 6 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS
Table 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS
Table 8 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 9 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 10 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 11 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY COUNTRY, 2013-2020 (USD MILLION)
Table 12 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
Table 13 EUROPE: TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 14 EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 15 EUROPE: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 16 EUROPE: IODINE-123 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 17 EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 18 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY COUNTRY, 2013-2020 (USD MILLION)
Table 19 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
Table 20 EUROPE: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 21 EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 22 EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 23 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 24 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 25 EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 26 EUROPE: BETA EMITTERS MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
Table 27 EUROPE: IODINE-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 28 EUROPE: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 29 EUROPE: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 30 EUROPE: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 31 EUROPE: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 32 EUROPE: OTHER BETA EMITTER ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 33 EUROPE: ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 34 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 35 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY ISOTOPE TYPE 2013-2020 (USD MILLION)
Table 36 EUROPE: IODINE-125 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 37 EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 38 EUROPE: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 39 EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 40 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 41 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 42 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
Table 43 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 44 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 47 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 48 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 49 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
Table 50 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 51 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 52 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 53 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 54 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 55 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
Table 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 61 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND)
Table 62 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY COUNTRY, 2013–2020 (THOUSAND)
Table 63 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND)
Table 64 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND)
Table 65 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND)
Table 66 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND)
Table 67 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BETA EMITTERS, BY TYPE, 2013–2020 (THOUSAND)
Table 68 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR ALPHA EMITTERS, BY TYPE, 2013–2020 (THOUSAND)
Table 69 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (THOUSAND)
Table 70 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 71 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 72 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 73 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 74 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 75 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 76 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 77 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 78 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 79 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013–2020 (USD MILLION)
Table 80 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 81 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 82 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 83 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 84 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 85 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 86 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 87 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 88 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 89 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013–2020 (USD MILLION)
Table 90 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 91 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 92 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 93 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 94 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 95 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 96 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 97 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 98 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 99 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 100 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 101 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 102 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 103 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 104 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 105 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 106 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 107 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 108 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 109 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 110 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 111 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 112 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 113 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 114 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 115 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 116 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 117 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 118 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 119 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 120 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 121 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 122 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 123 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 124 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 125 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 126 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 127 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 128 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 129 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013–2020 (USD MILLION)
Table 130 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 131 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 132 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 133 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 134 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 135 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 136 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 137 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 138 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 139 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 140 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 141 AGREEMENTS & CONTRACTS, 2012-2015
Table 142 ACQUISITIONS, 2012-2015
Table 143 MARKET DEVELOPMENTS, 2012-2015
Table 144 EXPANSIONS, 2012-2015
Table 145 OTHER STRATEGIES, 2012-2015
Table 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 5 LOW HEALTHCARE SPENDING IN EUROPE IS A MAJOR BURNING ISSUE IN THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET
Table 6 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS
Table 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS
Table 8 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 9 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 10 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 11 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY COUNTRY, 2013-2020 (USD MILLION)
Table 12 EUROPE: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
Table 13 EUROPE: TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 14 EUROPE: THALLIUM-201 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 15 EUROPE: GALLIUM-67 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 16 EUROPE: IODINE-123 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 17 EUROPE: OTHER SPECT ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 18 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY COUNTRY, 2013-2020 (USD MILLION)
Table 19 EUROPE: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
Table 20 EUROPE: FLUORINE-18 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 21 EUROPE: RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 22 EUROPE: OTHER PET ISOTOPES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 23 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 24 EUROPE: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION)
Table 25 EUROPE: BETA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 26 EUROPE: BETA EMITTERS MARKET SIZE, BY ISOTOPE TYPE, 2013-2020 (USD MILLION)
Table 27 EUROPE: IODINE-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 28 EUROPE: YTTRIUM-90 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 29 EUROPE: SAMARIUM-153 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 30 EUROPE: RHENIUM-186 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 31 EUROPE: LUTETIUM-177 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 32 EUROPE: OTHER BETA EMITTER ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 33 EUROPE: ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 34 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 35 EUROPE: BRACHYTHERAPY ISOTOPES MARKET SIZE, BY ISOTOPE TYPE 2013-2020 (USD MILLION)
Table 36 EUROPE: IODINE-125 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 37 EUROPE: IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 38 EUROPE: PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 39 EUROPE: CESIUM-131 MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)
Table 40 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY 2013-2020 (USD MILLION)
Table 41 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 42 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
Table 43 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 44 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 47 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 48 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 49 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
Table 50 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 51 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 52 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 53 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 54 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 55 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION)
Table 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION)
Table 61 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND)
Table 62 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURAL VOLUME, BY COUNTRY, 2013–2020 (THOUSAND)
Table 63 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND)
Table 64 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND)
Table 65 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2013–2020 (THOUSAND)
Table 66 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURAL VOLUME, BY TYPE, 2013–2020 (THOUSAND)
Table 67 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BETA EMITTERS, BY TYPE, 2013–2020 (THOUSAND)
Table 68 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR ALPHA EMITTERS, BY TYPE, 2013–2020 (THOUSAND)
Table 69 EUROPEAN NUCLEAR MEDICINE PROCEDURAL VOLUME FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (THOUSAND)
Table 70 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013–2020 (USD MILLION)
Table 71 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 72 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 73 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 74 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 75 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 76 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 77 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 78 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 79 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013–2020 (USD MILLION)
Table 80 GERMANY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 81 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 82 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 83 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 84 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 85 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 86 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 87 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 88 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 89 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013–2020 (USD MILLION)
Table 90 FRANCE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 91 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 92 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 93 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 94 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 95 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 96 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 97 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 98 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 99 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 100 ITALY: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 101 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 102 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 103 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 104 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 105 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 106 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 107 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 108 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 109 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 110 U.K.: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 111 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 112 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 113 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 114 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 115 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 116 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 117 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 118 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 119 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 120 SPAIN: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 121 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 122 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 123 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 124 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 125 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 126 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 127 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 128 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 129 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY APPLICATION, 2013–2020 (USD MILLION)
Table 130 RUSSIA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 131 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 132 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 133 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY TYPE, 2013–2020 (USD MILLION)
Table 134 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY TYPE, 2013–2020 (USD MILLION)
Table 135 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 (USD MILLION)
Table 136 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BETA EMITTERS, BY TYPE, 2013–2020 (USD MILLION)
Table 137 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY TYPE, 2013–2020 (USD MILLION)
Table 138 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY APPLICATION, 2013–2020 (USD MILLION)
Table 139 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET BY APPLICATION, 2013–2020 (USD MILLION)
Table 140 ROE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 (USD MILLION)
Table 141 AGREEMENTS & CONTRACTS, 2012-2015
Table 142 ACQUISITIONS, 2012-2015
Table 143 MARKET DEVELOPMENTS, 2012-2015
Table 144 EXPANSIONS, 2012-2015
Table 145 OTHER STRATEGIES, 2012-2015
LIST OF FIGURES
Figure 1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION
Figure 2 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
Figure 3 KEY DATA FROM SECONDARY SOURCES
Figure 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 RESEARCH DESIGN
Figure 8 DATA TRIANGULATION METHODOLOGY
Figure 9 THERAPEUTIC MARKET TO WITNESS HIGH GROWTH RATE FROM 2015 TO 2020
Figure 10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SHARE, BY TYPE, 2015 VS. 2020
Figure 11 GEOGRAPHICAL SNAPSHOT OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 2015
Figure 12 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS MARKET SIZE, 2015 VS. 2020
Figure 13 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH
Figure 14 GERMANY DOMINATES THE EUROPEAN SPECT NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015
Figure 15 REST OF EUROPE TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
Figure 16 DIAGNOSTIC SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
Figure 17 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
Figure 18 CLINICAL TRIALS STUDIES OF RADIOISOTOPES, BY COUNTRY
Figure 19 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE
Figure 20 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY COMPANY & INSTITUTE
Figure 21 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE
Figure 22 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE
Figure 23 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION
Figure 24 CLINICAL TRIALS FOR F-18, BY COUNTRY
Figure 25 CLINICAL TRIALS FOR F-18, BY PHASE
Figure 26 CLINICAL TRIALS FOR F-18, BY INDICATION
Figure 27 CLINICAL TRIALS FOR F-18, BY COMPANY/INSTITUTE
Figure 28 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE
Figure 29 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION
Figure 30 CLINICAL TRIALS FOR RA-223, BY COUNTRY
Figure 31 CLINICAL TRIALS FOR RA-223, BY PHASE
Figure 32 CLINICAL TRIALS FOR RA-223, BY INDICATION
Figure 33 CLINICAL TRIALS FOR RA-223, BY COMPANY/INSTITUTE
Figure 34 CLINICAL TRIALS FOR LU-177, BY COUNTRY
Figure 35 CLINICAL TRIALS FOR LU-177, BY PHASE
Figure 36 CLINICAL TRIALS FOR LU-177, BY INDICATION
Figure 37 CLINICAL TRIALS FOR LU-177, BY COMPANY/INSTITUTE
Figure 38 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE
Figure 39 THERAPEUTIC SEGMENT TO GROW AT A HIGHER CAGR OF 10.2%
Figure 40 PET SEGMENT TO GROW AT THE HIGHER CAGR OF 13.1% DURING THE FORECAST PERIOD
Figure 41 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.7% DURING THE FORECAST PERIOD
Figure 42 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE
Figure 43 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 13.2% DURING THE FORECAST PERIOD
Figure 44 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.1% DURING THE FORECAST PERIOD
Figure 45 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PET APPLICATIONS, BY TYPE
Figure 46 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 20.1% DURING THE FORECAST PERIOD
Figure 47 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.4% DURING THE FORECAST PERIOD
Figure 48 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE
Figure 49 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 16.5% DURING THE FORECAST PERIOD
Figure 50 THE ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 13.0% DURING THE FORECAST PERIOD
Figure 51 GERMANY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC IN 2015
Figure 52 THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET TO GROW AT A CAGR OF 8.2% DURING THE FORECAST PERIOD
Figure 53 BATTLE FOR MARKET SHARE: AGREEMENTS & CONTRACTS WAS THE KEY STRATEGY ADOPTED BY PLAYERS BETWEEN 2012 & 2015
Figure 54 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
Figure 55 MALLINCKRODT PLC: COMPANY SNAPSHOT
Figure 56 GE HEALTHCARE: COMPANY SNAPSHOT
Figure 57 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT
Figure 58 BAYER HEALTHCARE: COMPANY SNAPSHOT
Figure 59 NORDION, INC.: COMPANY SNAPSHOT
Figure 60 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
Figure 1 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION
Figure 2 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS
Figure 3 KEY DATA FROM SECONDARY SOURCES
Figure 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 7 RESEARCH DESIGN
Figure 8 DATA TRIANGULATION METHODOLOGY
Figure 9 THERAPEUTIC MARKET TO WITNESS HIGH GROWTH RATE FROM 2015 TO 2020
Figure 10 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SHARE, BY TYPE, 2015 VS. 2020
Figure 11 GEOGRAPHICAL SNAPSHOT OF THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 2015
Figure 12 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS MARKET SIZE, 2015 VS. 2020
Figure 13 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH
Figure 14 GERMANY DOMINATES THE EUROPEAN SPECT NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015
Figure 15 REST OF EUROPE TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
Figure 16 DIAGNOSTIC SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD
Figure 17 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
Figure 18 CLINICAL TRIALS STUDIES OF RADIOISOTOPES, BY COUNTRY
Figure 19 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY PHASE
Figure 20 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC RADIOISOTOPES, BY COMPANY & INSTITUTE
Figure 21 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE
Figure 22 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE
Figure 23 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION
Figure 24 CLINICAL TRIALS FOR F-18, BY COUNTRY
Figure 25 CLINICAL TRIALS FOR F-18, BY PHASE
Figure 26 CLINICAL TRIALS FOR F-18, BY INDICATION
Figure 27 CLINICAL TRIALS FOR F-18, BY COMPANY/INSTITUTE
Figure 28 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE
Figure 29 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION
Figure 30 CLINICAL TRIALS FOR RA-223, BY COUNTRY
Figure 31 CLINICAL TRIALS FOR RA-223, BY PHASE
Figure 32 CLINICAL TRIALS FOR RA-223, BY INDICATION
Figure 33 CLINICAL TRIALS FOR RA-223, BY COMPANY/INSTITUTE
Figure 34 CLINICAL TRIALS FOR LU-177, BY COUNTRY
Figure 35 CLINICAL TRIALS FOR LU-177, BY PHASE
Figure 36 CLINICAL TRIALS FOR LU-177, BY INDICATION
Figure 37 CLINICAL TRIALS FOR LU-177, BY COMPANY/INSTITUTE
Figure 38 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE
Figure 39 THERAPEUTIC SEGMENT TO GROW AT A HIGHER CAGR OF 10.2%
Figure 40 PET SEGMENT TO GROW AT THE HIGHER CAGR OF 13.1% DURING THE FORECAST PERIOD
Figure 41 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.7% DURING THE FORECAST PERIOD
Figure 42 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE
Figure 43 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 13.2% DURING THE FORECAST PERIOD
Figure 44 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.1% DURING THE FORECAST PERIOD
Figure 45 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PET APPLICATIONS, BY TYPE
Figure 46 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 20.1% DURING THE FORECAST PERIOD
Figure 47 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.4% DURING THE FORECAST PERIOD
Figure 48 SEGMENTATION OF EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE
Figure 49 REST OF EUROPE REGION TO GROW AT THE HIGHEST CAGR OF 16.5% DURING THE FORECAST PERIOD
Figure 50 THE ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 13.0% DURING THE FORECAST PERIOD
Figure 51 GERMANY TO COMMAND THE LARGEST SHARE OF THE EUROPEAN NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC IN 2015
Figure 52 THE EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET TO GROW AT A CAGR OF 8.2% DURING THE FORECAST PERIOD
Figure 53 BATTLE FOR MARKET SHARE: AGREEMENTS & CONTRACTS WAS THE KEY STRATEGY ADOPTED BY PLAYERS BETWEEN 2012 & 2015
Figure 54 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT
Figure 55 MALLINCKRODT PLC: COMPANY SNAPSHOT
Figure 56 GE HEALTHCARE: COMPANY SNAPSHOT
Figure 57 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT
Figure 58 BAYER HEALTHCARE: COMPANY SNAPSHOT
Figure 59 NORDION, INC.: COMPANY SNAPSHOT
Figure 60 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT
